Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16.
Nature. 2021.
PMID: 34135506
Clinical Trial.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group.
Bellmunt J, et al. Among authors: degaonkar v.
Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12.
Lancet Oncol. 2021.
PMID: 33721560
Free PMC article.
Clinical Trial.
Item in Clipboard
"Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
Drakaki A, Pantuck A, Mhatre SK, Dhillon PK, Davarpanah N, Degaonkar V, Surinach A, Chamie K, Grivas P.
Drakaki A, et al. Among authors: degaonkar v.
Urol Oncol. 2021 Jan;39(1):76.e15-76.e22. doi: 10.1016/j.urolonc.2020.07.011. Epub 2020 Aug 8.
Urol Oncol. 2021.
PMID: 32778476
Free article.
Item in Clipboard
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Drakaki A, Dhillon PK, Wakelee H, Chui SY, Shim J, Kent M, Degaonkar V, Hoang T, McNally V, Luhn P, Gutzmer R.
Drakaki A, et al. Among authors: degaonkar v.
Oncoimmunology. 2020 Oct 5;9(1):1824645. doi: 10.1080/2162402X.2020.1824645.
Oncoimmunology. 2020.
PMID: 33101774
Free PMC article.
Item in Clipboard
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
Powles T, Young A, Nimeiri H, Madison RW, Fine A, Zollinger DR, Huang Y, Xu C, Gjoerup OV, Aushev VN, Wu HT, Aleshin A, Carter C, Davarpanah N, Degaonkar V, Gupta P, Mariathasan S, Schleifman E, Assaf ZJ, Oxnard G, Hegde PS.
Powles T, et al. Among authors: degaonkar v.
Front Oncol. 2023 Jul 31;13:1221718. doi: 10.3389/fonc.2023.1221718. eCollection 2023.
Front Oncol. 2023.
PMID: 37601688
Free PMC article.
Item in Clipboard
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Sethi H, Aleshin A, Shi Y, Davarpanah N, Carter C, Bellmunt J, Mariathasan S.
Powles T, et al. Among authors: degaonkar v.
Eur Urol. 2024 Feb;85(2):114-122. doi: 10.1016/j.eururo.2023.06.007. Epub 2023 Jul 26.
Eur Urol. 2024.
PMID: 37500339
Item in Clipboard
Cite
Cite